High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well
LUNG CANCER (2013)
期刊
LUNG CANCER
卷 80, 期 1, 页码 102-105出版社
ELSEVIER IRELAND LTD
关键词
作者
我是这篇论文的作者
推荐
Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases
K. Tamura, T. Yoshida, K. Masuda, Y. Matsumoto, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
ESMO OPEN (2023)
Original Research Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer
Irlanda Peralta-Arrieta, Octavio A. Trejo-Villegas, Leonel Armas-Lopez, Hugo A. Ceja-Rangel, Maria Del Carmen Ordonez-Luna, Priscila Pineda-Villegas, Marco A. Gonzalez-Lopez, Blanca Ortiz-Quintero, Criselda Mendoza-Milla, Zyanya L. Zatarain-Barron, Oscar Arrieta, Joaquin Zuniga, Federico Avila-Moreno
EUROPEAN JOURNAL OF CANCER (2022)
Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
Shiqi Ma, Lu Zhang, Yuan Ren, Wei Dai, Tingqing Chen, Liping Luo, Juan Zeng, Kun Mi, Jinyi Lang, Bangrong Cao
ONCOGENE (2021)
Heterogeneity of glutamine metabolism in acquired-EGFR-TKI-resistant lung cancer
Suntae Kim, Jang Su Jeon, Yong June Choi, Ga Hee Baek, Sang Kyum Kim, Keon Wook Kang
LIFE SCIENCES (2022)
Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
CANCER RESEARCH (2022)
Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
Jingwei Li, Peiyi Li, Jun Shao, Shufan Liang, Yuntian Wan, Qiran Zhang, Changshu Li, Yalun Li, Chengdi Wang
CANCERS (2022)
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
SCIENTIFIC REPORTS (2022)
Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
Peijun Cao, Yongwen Li, Ruifeng Shi, Yin Yuan, Hao Gong, Guangsheng Zhu, Zihe Zhang, Chen Chen, Hongbing Zhang, Minghui Liu, Zhenhua Pan, Hongyu Liu, Jun Chen
FRONTIERS IN CHEMISTRY (2022)
Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
Dylan A. Farnsworth, Yankuan T. Chen, Georgia de Rappard Yuswack, William W. Lockwood
CELLS (2021)
Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
Lei Wen, Junjie Zhen, Changguo Shan, Mingyao Lai, Weiping Hong, Hui Wang, Mingting Ye, Yanying Yang, Shaoqun Li, Zhaoming Zhou, Jiangfen Zhou, Qingjun Hu, Juan Li, Xuwei Tian, Longhua Chen, Linbo Cai, Zhanhong Xie, Cheng Zhou
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2023)
EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease
Juan Diego Alzate, Reed Mullen, Elad Mashiach, Kenneth Bernstein, Fernando De Nigris Vasconcellos, Lauren Rotmann, Assaf Berger, Tanxia Qu, Joshua S. Silverman, John G. Golfinos, Bernadine R. Donahue, Douglas Kondziolka
JOURNAL OF NEURO-ONCOLOGY (2023)
EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease
Juan Diego Alzate, Reed Mullen, Elad Mashiach, Kenneth Bernstein, Fernando De Nigris Vasconcellos, Lauren Rotmann, Assaf Berger, Tanxia Qu, Joshua S. Silverman, John G. Golfinos, Bernadine R. Donahue, Douglas Kondziolka
JOURNAL OF NEURO-ONCOLOGY (2023)
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010-2019 Retrospective Cohort Study
Vineeth Tatineni, Patrick J. O'Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia
CANCERS (2023)
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment
Yan Wang, Xue Yang, Nan-Jing Li, Jian-Xin Xue
LUNG CANCER (2022)
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
Yaowen Song, Shuiyu Lin, Jun Chen, Jun Dang
BMC CANCER (2023)
Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals
Michiel van de Ven, Hendrik Koffijberg, Valesca Retel, Kim Monkhorst, Egbert Smit, Wim van Harten, Maarten IJzerman
JOURNAL OF MOLECULAR DIAGNOSTICS (2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
LANCET ONCOLOGY (2021)
Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach
Sanjay Popat, Neal Navani, Keith M. Kerr, Egbert F. Smit, Timothy J. P. Batchelor, Paul Van Schil, Suresh Senan, Fiona McDonald
ONCOLOGIST (2021)
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
Yi-Long Wu, Egbert F. Smit, Todd M. Bauer
CANCER TREATMENT REVIEWS (2021)
Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer
Anna-Larissa N. Niemeijer, Daniela E. Oprea-Lager, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Berlinda J. de Wit-van der Veen, Idris Bahce, Danielle J. Vugts, Guus A. M. S. van Dongen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen
JOURNAL OF NUCLEAR MEDICINE (2022)
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer
Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A. M. S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen
JOURNAL OF NUCLEAR MEDICINE (2022)
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
CLINICAL CANCER RESEARCH (2022)
INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Egbert F. Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M. Tho, Xiuning Le, Julien Mazieres, How S. Hin, Masahire Morise, Viola W. Zhu, Daniel Tan, Kristina H. Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M. Schumacher, Niki Karachaliou, Yi-Long Wu
FUTURE ONCOLOGY (2022)
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis
Pieter J. M. Joosten, Chris Dickhoff, Vincent van der Noort, Maarten Smeekens, Rachel C. Numan, Houke M. Klomp, Judi N. A. van Diessen, Jose S. A. Belderbos, Egbert F. Smit, Kim Monkhorst, Jan W. A. Oosterhuis, Michel M. van den Heuvel, Max Dahele, Koen J. Hartemink
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY (2022)
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design
Gregory J. Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Egbert F. Smit, Anne S. Tsao, Ann Alcasid, Tiziana Usari, Paul S. Wissel, Keith D. Wilner, Bruce E. Johnson
FUTURE ONCOLOGY (2022)
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer
Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson
JOURNAL OF CLINICAL ONCOLOGY (2023)
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne
JOURNAL OF CLINICAL ONCOLOGY (2023)
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu
JOURNAL OF CLINICAL ONCOLOGY (2023)
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
Rolof G. P. Gijtenbeek, Vincent van der Noort, Joachim G. J. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D. J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E. E. M. van den Borne, Harry J. M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
ERJ OPEN RESEARCH (2022)